EGFR and metastatic neoplasm: Approximately, 20%‐25% of new cases of colorectal cancer are metastatic (mCRC) at diagnosis and up to 50% of all patients eventually develop metastatic disease.1, 2, 3, 4 During the last decade, improvements in the treatment of mCRC patients have increased the median survival from 12 to 21 months.5 Survival improvements can be attributed to the development of the antiangiogenic agent bevacizumab and monoclonal antibody (mAb) therapies that target the epidermal growth factor receptor (EGFR), primarily panitumumab and cetuximab.6